What is Icosavax, Inc. (ICVX) stock price today?

Icosavax, Inc. (ICVX) is currently trading at $15.31, down 0.91% today.

What is ICVX P/E ratio?

Icosavax, Inc.'s P/E ratio is -6.87. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ICVX return on equity (ROE)?

Icosavax, Inc.'s return on equity (ROE) is -35.64%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Icosavax, Inc.'s market cap?

Icosavax, Inc. has a market capitalization of $769.04M.

NASDAQ · Biotechnology

Icosavax, Inc. (ICVX) Stock

$15.31 -0.91% NASDAQ: ICVX Healthcare

Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases.

Valuation

Metric	Value
Price	$15.31
Market Cap	$769.04M
P/E Ratio	-6.87
P/B Ratio	2.79
P/S Ratio	1321.37
EPS (TTM)	$-2.23
52-Week High	$16.11
52-Week Low	$4.75
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-35.64%
ROA	-37.06%
ROCE	-42.27%
Gross Margin	-216.67%
Operating Margin	-9500.00%
Net Margin	-8800.00%
Debt/Equity	0.04
Current Ratio	16.24

Annual Financials (USD)

Metric	2019	2020	2021	2022
Revenue	$0	$2.0M	$8.0M	$1.0M
Operating Profit	$-5.0M	$-19.0M	$-66.0M	$-95.0M
Net Profit	$-5.0M	$-19.0M	$-68.0M	$-88.0M
EPS	$-0.51	$-6.67	$-3.78	$-2.23
Op Margin	—	-1157.8%	-844.2%	-16333.0%

Balance Sheet (USD)

Metric	2019	2020	2021	2022
Total Assets	$23.0M	$16.0M	$288.0M	$239.0M
Total Liabilities	$32.0M	$43.0M	$9.0M	$21.0M
Cash	$23.0M	$13.0M	$279.0M	$59.0M
Borrowings	$0	$5.0M	$0	$9.0M

Latest News

Amazon Advertising Up 26% In Q2, Profits Soar To $62.6B MediaPost · Jul 31, 2026 History Says That Nvidia Is an Unbelievable Bargain Right Now Motley Fool · Jul 31, 2026 UNITE HERE Local 11 Releases Letter Urging Greene County Ohio Board of Commissioners and Captain Tony Buschur to Consider Aramark’s Problematic Track Record in Prison Food Service and Award Contract to Alternate Provider Business Wire · Jul 31, 2026 Dow Jones Futures: Apple, Amazon Diverge Late; What To Do After AI Stocks Surge Investor's Business Daily · Jul 31, 2026 Anthropic's models gained unauthorized 'real-world' access during testing AFP · Jul 31, 2026

Cash Flow (USD)

Metric	2019	2020	2021	2022
Operating Cash Flow	$-5.0M	$-14.0M	$-39.0M	$-62.0M
Investing Cash Flow	$0	$0	$-2.0M	$-181.0M
Financing Cash Flow	$27.0M	$7.0M	$305.0M	$10.0M
Net Cash Flow	$22.0M	$-8.0M	$265.0M	$-221.0M
Free Cash Flow	$-5.0M	$-14.0M	$-40.0M	$-73.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-47.24
EV / EBITDA	-7.63
FCF Yield	-9.46%
Quick Ratio	16.24
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALBOAlbireo Pharma, Inc.	$44.15	+0.00%	-5.61	$915.89M	0.00%
ASLNASLAN Pharmaceuticals Limited	$0.60	-14.27%	-0.06	$777.12M	0.00%
CDMOAvid Bioservices, Inc.	$12.49	+0.00%	-5.60	$798.90M	0.00%
CMRXChimerix, Inc.	$8.54	+0.00%	-8.63	$801.08M	0.00%
EXAIExscientia plc	$4.84	—	-3.06	$633.18M	0.00%

About Icosavax, Inc.

Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.

Icosavax, Inc. is headquartered in US.

Icosavax, Inc. (ICVX) stock trades at $15.31 with a market capitalization of $769.04M. The stock is valued at a price-to-earnings (P/E) ratio of -6.87, price-to-book of 2.79, price-to-sales of 1321.37. Over the past 52 weeks the stock has ranged between $4.75 and $16.11, and currently trades 5.0% below its 52-week high.

On profitability, Icosavax, Inc. generates a return on equity (ROE) of -35.64%, return on capital employed of -42.27%, an operating margin of -9500.00%, a net profit margin of -8800.00%.

Official website: icosavax.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides